View Older Stories View More Recent Stories

Oct 31, 2019 07:30AM Intellia Therapeutics Announces Third Quarter 2019 Financial Results
Oct 24, 2019 08:00AM Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2019 Earnings and Company Update
Oct 24, 2019 07:30AM Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)
Oct 16, 2019 08:00AM Intellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)
Sep 30, 2019 08:00AM Intellia Therapeutics to Present at October Healthcare Investor Conferences
Sep 26, 2019 04:31PM Intellia Therapeutics (NTLA) Says Arbitration Decision Affirms its Interpretation of Licensing Agreement with Caribou Biosciences on CRISPR/Cas9 Technology
Sep 26, 2019 04:30PM Arbitration Decision Affirms Intellia Therapeutics’ Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology
Aug 1, 2019 07:30AM  Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update
Jul 30, 2019 08:00AM Intellia Therapeutics to Present at August Healthcare Investor Conference
Jul 25, 2019 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company Update
May 30, 2019 04:30PM Intellia Therapeutics to Participate at June Healthcare Investor Conferences
May 28, 2019 07:51AM Intellia Therapeutics (NTLA) Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer
May 28, 2019 07:50AM Intellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer
May 2, 2019 07:30AM Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update
Apr 29, 2019 07:30AM Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy
Apr 25, 2019 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update
Apr 15, 2019 04:30PM Intellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy
Feb 27, 2019 06:30AM Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
Jan 24, 2019 07:10AM Intellia Therapeutics (NTLA) Appoints Fred Cohen M.D. to Board
Jan 24, 2019 07:00AM Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors
Dec 6, 2018 07:32AM Intellia Therapeutics (NTLA) and Novartis (NVS) Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing
Dec 6, 2018 07:30AM Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population
Nov 8, 2018 04:30PM Intellia Therapeutics to Present at November Healthcare Investor Conferences
Oct 31, 2018 07:30AM Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments
Oct 30, 2018 04:30PM Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments
Oct 29, 2018 04:41PM Intellia Therapeutics (NTLA) Names Glenn Goddard as CFO
Oct 29, 2018 04:30PM Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer
Oct 18, 2018 08:33AM Intellia Therapeutics (NTLA) Highlights New Data in In-Vivo and Ex-Vivo Programs
Oct 18, 2018 08:30AM Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell Therapy
Sep 24, 2018 08:30AM Intellia Therapeutics to Present at October Healthcare Investor Conferences
Sep 10, 2018 04:34PM CRISPR (CRSP), Intellia (NTLA) and Caribou Provide Update on U.S Federal Circuit Decision Upholding Ruling by USPTO in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology
Sep 10, 2018 04:30PM CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Re
Sep 10, 2018 07:00AM F-star Appoints Nessan Bermingham as Chairman of its Board of Directors
Aug 27, 2018 08:00AM Intellia Therapeutics to Present at September Healthcare Investor Conferences
Aug 23, 2018 04:01PM Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution
Aug 23, 2018 08:30AM Intellia Therapeutics to Host Educational Briefing Webinar on Interference Proceedings Relating to CRISPR/Cas9 Genome Editing Technology Patents
Aug 1, 2018 07:30AM Intellia Therapeutics Announces Second Quarter 2018 Financial Results
Jun 19, 2018 09:07AM CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA) and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing
Jun 19, 2018 09:05AM CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing
May 17, 2018 07:30AM Intellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American Society of Gene and Cell Therapy 21st Annual Meeting
May 14, 2018 07:32AM Intellia Therapeutics (NTLA) Announces New Scientific Advisors Focused on Cell Therapy in Immuno-Oncology and Autoimmunity
May 14, 2018 07:30AM New Scientific Advisors Focused on Cell Therapy in Immuno-Oncology and Autoimmunity Join Intellia Therapeutics
May 1, 2018 07:30AM Intellia Therapeutics Announces First Quarter 2018 Financial Results
Apr 23, 2018 09:29AM UPDATE -- Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st Annual Meeting
Apr 23, 2018 08:30AM Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st Annual Meeting
Mar 14, 2018 07:30AM Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
Feb 28, 2018 04:30PM Intellia Therapeutics to Present at March Healthcare Investor Conferences
Feb 27, 2018 09:31AM Intellia (NTLA) Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using LNP Delivery Technology
Feb 27, 2018 09:28AM Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology
Jan 31, 2018 04:30PM Intellia Therapeutics to Present at February Healthcare Investor Conferences
View More Recent Stories View Older Stories